Skip to main content

Solid Tumor Clinical Trials

 

St. Jude Clinical Trials

3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

B7-H3-specific Chimeric Antigen Receptor Autologous T-cell Therapy for Pediatric Patients with Solid Tumors (3CAR)

Diseases Treated:

Solid Tumors

Eligibility:

Inclusion criteria include:

  • 21 years old or younger
  • Relapsed or refractory B7-H3-positive solid tumor
View Trial

ANGIO-A: Study of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Children and Young Adults with Solid Tumors

Safety and Tolerability of Oral Cyclophosphamide and Sorafenib with Intravenous Bevacizumab with the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Diseases Treated:

Solid tumors
Hepatocellular carcinoma
Fibrolamellar hepatocellular carcinoma
Sarcomas
Malignant rhabdoid tumors
Desmoplastic small round cell tumors

Eligibility:

Part 1

  • 1–30 years old
  • Diagnosis of a solid tumor that has grown or has come back after treatment
  • Tumor accessible through biopsy

Part 2

  • 1–30 years old
  • Diagnosis of:
    • Hepatocellular carcinoma that has grown or has come back after treatment
    • Fibrolamellar hepatocellular carcinoma
    • Desmoplastic small round cell tumor
    • Malignant rhabdoid tumor that is not in the central nervous system
  • Tumor accessible through biopsy
View Trial

AOST2032: Cabozantinib with Chemotherapy for Osteosarcoma

A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Diseases Treated:

Osteosarcoma

Eligibility:

  • Less than 40 years old
  • A new diagnosis of high-grade osteosarcoma
  • Must be able to swallow tablets
  • The current phase is only open to patients with metastatic disease
  • View Trial

    FLOPET: PET Scan Studies to Analyze Neuroblastoma and Pheochromocytoma Tumors

    18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

    Diseases Treated:

    Neuroblastoma, pheochromocytoma

    Eligibility:

    This study is open to St. Jude patients only.

    • Known or suspected neuroblastoma or pheochromocytoma
    • At least 1 year old

     

    View Trial

    NRSTS2021: A Risk Adapted Study Using Pazopanib, Radiation Therapy, and Selinexor for Non-Rhabdomyosarcoma Soft Tissue Sarcoma

    NRSTS2021: A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy, and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

    Diseases Treated:

    Non-rhabdomyosarcoma soft tissue sarcoma

    Adipocytic neoplasm

    Liposarcoma

    Synovial sarcoma

    MPNST

    Undifferentiated Sarcoma

    Eligibility:

    • Newly diagnosed non-rhabdomyosarcoma soft tissue sarcoma
    • Up to 30 years old 
    View Trial

    ONITT: Study of Onivyde with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma

    Phase 1/2 Study of Onivyde in combination with Talazoparib or Temozolomide in Children and Young Adults with Recurrent/Refractory Solid Tumors and Ewing Sarcoma

    Diseases Treated:

    Solid tumors
    Ewing sarcoma

    Eligibility:

    • Ages 12 months old to 30 years
    • Diagnosed with recurrent or refractory solid tumor (Phase 1)
    • Diagnosed with recurrent or refractory Ewing sarcoma (Phase 2)
    View Trial

    RBAPP: Smartphone App for Retinoblastoma

    Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

    Diseases Treated:

    Retinoblastoma

    Eligibility:

    This study is currently open only to patients at St. Jude Children's Research Hospital.

    • 7 years old or younger
    • Part I
      • Diagnosed with retinoblastoma and has not received any treatment OR
      • Diagnosed with cataracts and has not received any treatment OR
      • Diagnosed with glaucoma and has not received any treatment
    • Part II
      • Referred to an eye doctor to check for leukocoria or other eye conditions
    • Part III
      • Diagnosed with retinoblastoma and is receiving treatment
    View Trial

    RMS2021: Treatment of Intermediate- and High-risk Pediatric Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan

    RMS2021: A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children with Intermediate- and High-risk Disease.

    Diseases Treated:

    Rhabdomyosarcoma

    Eligibility:

    • Newly diagnosed with rhabdomyosarcoma (RMS) of any subtype
    • Low-risk, intermediate-risk, or high-risk disease, as defined in the research protocol
    • Up to 21 years old
    • No prior radiotherapy or chemotherapy
    • No active infection
    View Trial

    Collaborative Clinical Trials

    ARST2032: Very Low-Risk and Low-Risk Rhabdomyosarcoma Study

    Diseases Treated:

    Rhabdomyosarcoma

    Eligibility:

    • Enrolled in the APEC14B1 clinical trial and consent to DNA testing before being enrolled and treated on this ARST2032 trial.
    • Up to 21 years old
    • Newly diagnosed embryonal rhabdomyosarcoma (ERMS), spindle cell/sclerosing RMS, or FOXO1 fusion negative alveolar rhabdomyosarcoma (ARMS) 
    View Trial

    LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors

    Diseases Treated:

    Solid tumors, Brain tumors

    Eligibility:

    • 6 months to 21 years old
    • Solid tumor or brain tumor that has progressed or spread
    • Failed standard treatment
    • RET gene alteration
    View Trial

    MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma

    Eligibility:

    • This clinical trial is currently closed to accrual.
    • Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
    • Between 12 years and 18 years old with diagnosis of melanoma OR
    • Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
    • Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered. 
    • Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
    • Appropriate liver and kidney functions
    View Trial

    NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma

    Diseases Treated:

    Neuroblastoma, ganglioneuroblastoma

    Eligibility:

    • Participant has been enrolled on ANBLB1 (ANBL00B1).
    • Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
    • Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.

     

    View Trial

    Adrenocortical Tumors and International Pediatric Adrenocortical Tumor Registry (IPACTR)

    The International Pediatric Adrenocortical Tumor Registry (IPACTR) contains data about children and teens who have adrenocortical tumor or ACT.

    ACT is a rare type of cancer. It affects a very small number of children each year. That small number makes getting data difficult. Scientists at St. Jude started collecting details about children around the world who have had ACT.

    The result is IPACTR. Experts use the IPACTR data to help understand ACT and help design research studies that aim to find new and better treatments.

     
     
    Close